TI
SIOX

Telemetry Investments’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Telemetry Investments’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,500
Closed -$138K – 158
2017
Q3 		$138K Buy
+2,500
New +$422K 0.05% 136
2017
Q2 		– Sell
-2,125
Closed -$254K – 129
2017
Q1 		$254K Buy
2,125
+250
+13% +$26.2K 0.11% 93
2016
Q4 		$186K Buy
1,875
+250
+15% +$26.3K 0.11% 90
2016
Q3 		$182K Buy
+1,625
New +$195K 0.11% 92

Other funds holding SIOX

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Telemetry Investments's SIOX Position: Q4 2017 in Review

Telemetry Investments sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 2,500 shares — an estimated $138K sold.

Telemetry Investments first reported a position in SIOX in Q3 2016 and held it in 4 quarters. The position peaked at $254K in Q1 2017. 105 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Telemetry Investments reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Telemetry Investments sold 2,500 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $138K.
  • Telemetry Investments first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2016 and held it in 4 quarters.
  • Telemetry Investments's Sio Gene Therapies Inc. Common Stock position peaked at $254K in Q1 2017.
  • 105 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Telemetry Investments's 13F filing for Q4 2017, filed 14 Feb 2018.